All In Biotech

Drug Trial Radar · NCT06385145

A Bioavailability Study of Two Different PEG-rhGH Preparations.

A Randomized, Open-label, Single Dose, 2-period Crossover Bioavailability Study of Two Different Polyethylene Glycol Recombinant Human Growth Hormone(PEG-rhGH) Preparations in Chinese Healthy Adult Male Subjects

Last checked: Nov 20, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

May 8, 2024

Primary completion

Jul 5, 2024

Study completion Mar 26, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations.

Conditions

  • Pediatric Growth Hormone Deficiency (PGHD)

Interventions

  • PEG-rhGH with new preparation (T)Drug

    A single subcutaneous injection of PEG-rhGH with new preparation

  • PEG-rhGH with present preparation (R)Drug

    A single subcutaneous injection of PEG-rhGH with present preparation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (Peak Plasma Concentration (Cmax) ) of PEG-rhGH with present and new preparationTime frame: 0 hours -192 hours post-administration
  2. Pharmacokinetics (Area under the concentration-time curve from time zero to time infinity (AUC0-inf)) of PEG-rhGH with present and new preparationTime frame: 0 hours -192 hours post-administration
  3. Pharmacokinetics (Area under the concentration-time curve from time zero to the time of the last quantifiable (AUC0-last)) of PEG-rhGH with present and new preparationTime frame: 0 hours -192hours post-administration
  4. Safety and tolerability (Number of participants with treatment-related adverse events)Time frame: up to approximately 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chengdu Xinhua Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.